REVIEW A key building block used by Novartis in the synthesis of compounds patented for treating, inhibiting, or preventing pathology conditions or disorders mediated by deacetylases enzymes. This would allow undesired proliferative conditions, neurodegenerative diseases, cardiovascular diseases, strokes, autoimmune diseases, inflammatory diseases, undesired immunology processes, and fungal infections to be potentially targeted for pharmacological treatment.
REFERENCES
[1]
M Shultz, CHT Chen, YS Cho, L Jiang, J Fan, G Liu, D Majumdar. Preparation of heterocyclic hydroxamate-based inhibitors of deacetylases for treating cancer and other diseases PCT Int. Appl. (2009), WO 2009118305 A1 20091001
All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
![943133-29-7 2-(1-Hydroxy-1-methyl-1-ethyl)-pyrazolo[1,5-a]pyridine-3-carbaldehyde AKSci B235](/images/header-logo.png "943133-29-7 2-(1-Hydroxy-1-methyl-1-ethyl)-pyrazolo[1,5-a]pyridine-3-carbaldehyde AKSci B235"){kind=logo}
Add to Favorites 
Delete from Favorites 
